Dr. Susan F. Slovin discusses her recent paper that examined abiraterone with and without cabazitaxel for mCRPC. Chana Weinstock, MD joins the podcast to give career advice and answer our questions about the FDA. We're joined by Walter M. Stadler, MD, to discuss how academic papers are accepted and the steps to take when submitting one. Neeraj Agarwal, MD, joins us to discuss the TALAPRO-2 study and the relevance of homologous recombination repair biomarkers. Karim Fizazi, MD, PhD, discusses the radiotherapy components of the PEACE-1 study on abiraterone and prednisone added to ADT. Karim Fizazi joins us at ASCO 2023 to discuss results from the TALAPRO-2 study on talazoparib plus enzalutamide for mCRPC. Professor Nick James discusses the success of the STAMPEDE trial on the use of abiraterone in patients with prostate cancer. An ODAC meeting determined that olaparib plus abiraterone for mCRPC should be restricted to patients with BRCA mutations. Amar Kishan, MD, discusses his recent meta-analysis on the effects of concurrent neoadjuvant versus adjuvant sequencing. The latest topics in urologic oncology are discussed at the 14th International Uro-Oncology Conference in Brazil. Ursula Vogl, MD, discusses her research and career progression in the prostate and renal cell cancer fields. Karine Tawagi, MD, from the University of Illinois, discusses her work in immune-related toxicities. The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial. Neeraj Agarwal, MD, FASCO, describes positive data from the TALAPRO-2 study on talazoparib and enzalutamide for mCRPC. Michael Morris, MD discusses PARP inhibition for castration-resistant prostate cancer and the differing opinions on its use. The Uromigos discuss the cost of quality adjusted life years with Daniel Goldstein, MD, from Davidoff Cancer Center. A summary of the prostate and bladder cancer session of the Conversations & Trending Topics in GU Cancers conference. Chris Sweeney, MBBS, joins The Uromigos to discuss 2022 research as well as further studies to be carried out in 2023. Drs. Silke Gillessen and Dan George debate the use of olaparib and abiraterone in selected or unselected patients with mCRPC. The Uromigos chat with Axel Merseburger about his paper on continuing enzalutamide with docetaxel for the treatment of CRPC.